A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 14830 participants.

Also called NCT05643573

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 14,830 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05643573
  • EudraCT 2022-000758-28
Other papers using this trial's data
  • Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial JAMA cardiology, 2025-06-01 DOI, PubMed 40136309, PMC11947966 Not in the PMC Open Access subset.
  • Asundexian versus Apixaban in Patients with Atrial Fibrillation The New England journal of medicine, 2025-01-02 DOI, PubMed 39225267

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Latvia, Lithuania, Malaysia, Netherlands, Norway, Poland, Portugal, Romania, Singapore, Slovakia, South Korea, Spain, Sweden, Switzerland, Taiwan, Türkiye, United Kingdom (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT05643573. Randomized; quadruple masking; primary purpose treatment. Start 2022-12-05 (actual); primary completion 2024-01-31 (actual). Results posted on 2024-12-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke
Acronym
OCEANIC-AF
Condition
Prevention of Stroke or Systemic Embolism
Intervention (Drug)
Asundexian (BAY2433334)
Intervention (Drug)
Apixaban
Intervention (Drug)
Asundexian matching placebo
Intervention (Drug)
Apixaban matching placebo
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct05643573
Content hash
a63ef33f041cb93a049ff79e4e6e398ace760bb6e45fd0970071935288f24954